Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer.

Trial Profile

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2016

At a glance

  • Drugs Basiliximab (Primary) ; Ciclosporin
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2012 Planned end date changed from 1 Sep 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 15 May 2012 Actual patient number 17 added as reported by ClinicalTrials.gov.
    • 15 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top